N. Wilsher

发表

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.

G. Chessari, P. Williams, E. J. Lewis, 2015, Journal of medicinal chemistry.

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity

P. Workman, F. Chan, R. T. te Poele, 2007, Molecular Cancer Therapeutics.

Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).

G. Chessari, P. Williams, E. Chiarparin, 2017, Journal of medicinal chemistry.

A validated liquid chromatography‐tandem mass spectroscopy method for the quantification of tolinapant in human plasma

N. Wilsher, A. Oganesian, Vanessa Martins, 2022, Analytical Science Advances.

Phytoestrogens as natural prodrugs in cancer prevention: a novel concept

V. Androutsopoulos, N. Wilsher, R. Arroo, 2008, Phytochemistry Reviews.

Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene

Donald J L Jones, A. Gescher, P. Farmer, 2004, British Journal of Cancer.

Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.

P. Workman, A. Faisal, R. Bayliss, 2010, Journal of medicinal chemistry.

A validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma.

F. Raynaud, N. Wilsher, Yasmin Asad, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450.

V. Androutsopoulos, N. Wilsher, R. Arroo, 2009, Cancer letters.

The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.

Dyan N. Ankrett, N. Wilsher, K. Ruparelia, 2019, Bioorganic & medicinal chemistry letters.

A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one

G. Chessari, P. Williams, G. Saxty, 2018, Journal of medicinal chemistry.

2 CYTOCHROME P 450 CYP 1 METABOLISM OF HYDROXYLATED FLAVONES AND FLAVONOLS : SELECTIVE BIOACTIVATION OF LUTEOLIN IN BREAST CANCER CELLS

D. Spandidos, V. Androutsopoulos, N. Wilsher, 2017 .

ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth

G. Chessari, J. Lyons, N. Thompson, 2018, Molecular Cancer Therapeutics.

A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies

L. Fazal, N. Wilsher, Vanessa Martins, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: Selective bioactivation of luteolin in breast cancer cells.

D. Spandidos, A. Tsatsakis, V. Androutsopoulos, 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

C. Murray, V. Berdini, J. Lyons, 2021, Molecular Cancer Therapeutics.

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.

I. McLay, S. Phipps, M. Belvisi, 2001, Bioorganic & medicinal chemistry.

Phytoestrogens as natural prodrugs in cancer prevention: dietary flavonoids

V. Androutsopoulos, N. Wilsher, K. Ruparelia, 2009, Phytochemistry Reviews.

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, L. Fazal, 2021, Journal of medicinal chemistry.

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, J. Castro, 2018, Journal of medicinal chemistry.

The Phosphoinositide-Specific Phospholipase C Inhibitor U73122 (1-(6-((17β-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) Spontaneously Forms Conjugates with Common Components of Cell Culture Medium

R. Ruddle, W. Aherne, F. Raynaud, 2007, Drug Metabolism and Disposition.

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.

I. McLay, N. Wilsher, M. Foster, 2001, Bioorganic & medicinal chemistry letters.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

M. Noble, J. Endicott, G. Chessari, 2021, Journal of medicinal chemistry.

Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase.

F. Holding, G. Chessari, R. Walser, 2024, Journal of medicinal chemistry.